Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial-Reference-Cited by-同舟云学术

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Published:2012-04 Issue:9825 Volume:379 Page:1498-1507
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Garber Alan J,King Allen B,Prato Stefano Del,Sreenan Seamus,Balci Mustafa K,Muñoz-Torres Manuel,Rosenstock Julio,Endahl Lars A,Francisco Ann Marie Ocampo,Hollander Priscilla

Publisher

Elsevier BV

Subject

General Medicine

Reference27 articles.

1. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group;Turner;JAMA,1999

2. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes;Cryer;Diabetologia,2002

3. Insulin degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation;Jonassen;Diabetes,2010

4. The pharmacodynamic variability of insulin degludec is consistently lower than insulin glargine over 24 hours at steady state;Heise;Diabetes,2011

5. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine;Heise;Diabetes,2011

Cited by 300 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of insulin degludec biosimilar B01411 versus originator insulin degludec in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs: a multicenter, randomized, open-label, phase 3 study;Current Medical Research and Opinion;2024-09-05

2. Once‐weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant‐level meta‐analysis of the ONWARDS 1–5 trials;Diabetes, Obesity and Metabolism;2024-07

3. Ensuring patient safety when managing concentrated insulin glargine and insulin degludec at hospital admission;JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY;2024-07

4. Clinical perspectives on the frequency of hypoglycemia in treat-to-target randomized controlled trials comparing basal insulin analogs in type 2 diabetes: a narrative review;BMJ Open Diabetes Research & Care;2024-05

5. Traiter les hypoglycémies iatrogènes à l’ère des nouvelles technologies;Médecine des Maladies Métaboliques;2024-05